Transgene Stock

Transgene P/B

The P/B (Price-to-Book Ratio) of Transgene (TNG.PA) as of Aug 7, 2026 is 15.31. In the previous year, P/B (Price-to-Book Ratio) was 14.91 — a change of 2.68% (higher).

P/B

15.31

YoY

2.68%

Last updated:

P/B (Price-to-Book Ratio) of Transgene is 2026 15.31 . P/B (Price-to-Book Ratio) of Transgene was 2025 14.91 . It decreases by 2.68% higher compared to the previous year.
Access this data via the Eulerpool API
Get Free API Key

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

P/B (Price-to-Book Ratio) of Transgene is 15.31 in 2026.

P/B (Price-to-Book Ratio) of Transgene changed from 14.91 to 15.31, representing a 2.68% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Transgene since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Transgene with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API
Get Free API Key

Valuation — Transgene

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueEV/EBITForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Transgene